Proactively evaluate Merck KGaA’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
|Event Date||Event Type||Company Name||Ticker Symbol||Drug Name||Therapy Area||Indication||Source Type|
|13 Sep 2019||GDCTXXXX||Lorem||Lorem||Lorem||XXXX||Planned||Lorem|
|11 Sep 2019||Phase I Trial Completion||Merck KGaA; PPD Inc||MRK||Novothyrox||Hormonal Disorders; Oncology||Goiter; Graves Diseases; Hashimoto Thyroiditis; Hypothyroidism; Thyroid Cancer; Thyroid Gland Disorders||Clinical Trial Registry|
|02 Sep 2019||Phase I Trial Completion||EMD Serono Research & Development Institute Inc; Merck KGaA||MRK||M-3541||Oncology||Head And Neck Cancer; Solid Tumor||Clinical Trial Registry|
|01 Sep 2019||Phase IV Trial Initiation||Merck KGaA; University of Munster||MRK||cladribine||Central Nervous System||Multiple Sclerosis; Relapsing Multiple Sclerosis (RMS)||Clinical Trial Registry|
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer